Dilawar Khokhar, MD
Allergy & Immunology · Germantown, MDNPI 1760836589
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,215 of the $14,020 with a category attached, or 72.9%. Blueprint Medicines Corporation accounts for 85.3% of it on its own, with 14 other manufacturers making up the rest.
Across 61 payments — averaging $229.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$12K
- Sanofi$995
- AstraZeneca$314
- Regeneron Healthcare Solutions, Inc.$157
- GSK$100
- ARS Pharmaceuticals Operations, Inc.$97
- plus $395 from 9 others
What the payments were for
- Speaking & faculty fees$10,21573%
- Grants$7005%
- Travel & lodging$1,53811%
- Food & beverage$1,54211%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 14 | $11,961 |
| Sanofi | 5 | $995 |
| AstraZeneca | 13 | $314 |
| Regeneron Healthcare Solutions, Inc. | 5 | $157 |
| GSK | 4 | $100 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $97 |
| Novartis | 4 | $84 |
| Genentech USA, Inc. | 2 | $59 |
| Ionis Pharmaceuticals, Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Biocryst US Sales Co., LLC | 2 | $48 |
| Alk-abello, Inc | 1 | $29 |
| Lilly USA, LLC | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Greer Laboratories, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AYVAKIT$9,764
How this compares
$14,020 in reported general payments places this provider in the 80th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $64,279 |
| Epinephrine | 13 | $2,768 |
| Montelukast Sodium | 34 | $549 |
| Ipratropium Bromide | 15 | $484 |
| Azelastine Hcl | 12 | $376 |
| Levocetirizine Dihydrochloride | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Germantown
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
- Sally BaileyBaltimore$344K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
- Nasim ReedyGaithersburg$63K
- Kristin SokolRockville$62K
- Rachel SchreiberRockville$48K
- Eric OliverBaltimore$31K
- Matthew MardineyBel Air$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.